MarketPulse
T

$TEVA

22 articles found
17 positive
2 negative
3 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Duvakitug Shows Sustained Remission in Phase 2b Trial for Inflammatory Bowel Disease

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.
SNYTEVAmonoclonal antibodyinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider Research

Uterine Fibroid Treatment Market Poised for 7.63% Annual Growth Through 2033

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.
JNJPFEABBVSYKMDT+9market growthminimally invasive procedures